Skip to main content
. Author manuscript; available in PMC: 2017 Nov 22.
Published in final edited form as: Handb Exp Pharmacol. 2009;(188):165–196. doi: 10.1007/978-3-540-71029-5_8

Table 3B.

Phenotypic analyses of human DC subsets

DC Subsetb CD11c CD123 CCR6 CD4 BDCA2 References
Myeloid (mDCs) + − ? + − (Dzionek et al. 2000)
(Nair et al. 2004)
Plasmacytoid (pDCs) − + ? + + (Dzionek et al. 2000)
(Patterson et al. 2001)
(Hochrein et al. 2002)
(Janke et al. 2006)
(Cravens et al. 2007)
(Grage-Griebenow et al. 2007)
IDO-competent (CD19+) pDCs − + + + + (Munn et al. 2002)
(Boasso et al. 2005)
(Boasso et al. 2007)
b

Based on analyses of human DCs derived from pBMCs; leukocyte lineage (lin) negative (null for CD3, CD14, CD19, CD56) and HLA-DR, CD4 or CD33 positive.